Abstract
The diabetic foot remains a major cause of morbidity worldwide. Ischaemia due to peripheral arterial disease significantly contributes to its pathogenesis and natural history. Increased revascularisation has been decisive in improving outcomes. However, there is still a need for further improvement. Advances in the treatment of ischaemia in the diabetic foot include therapeutic angiogenesis, stem cell therapy and miscellaneous modalities. Angiogenesis has yielded encouraging results in the treatment of peripheral arterial disease, but it has not been studied enough in patients with diabetes. Choice of patients, reliable study endpoints, as well as safety of growth factors in diabetic patients, who have an excess risk of widespread vascular disease, need to be addressed more convincingly. Similar improvement is required in the other emerging therapeutic options. From a practical point of view, until novel modalities are available, increased vigilance and prompt aggressive revascularisation are indispensable to reduce the rate of amputations.
Keywords: Angiogenesis, diabetic foot, ischaemia, peripheral arterial disease
Current Vascular Pharmacology
Title: Advances in Treating the Ischaemic Diabetic Foot
Volume: 6 Issue: 1
Author(s): Nikolaos Papanas and Efstratios Maltezos
Affiliation:
Keywords: Angiogenesis, diabetic foot, ischaemia, peripheral arterial disease
Abstract: The diabetic foot remains a major cause of morbidity worldwide. Ischaemia due to peripheral arterial disease significantly contributes to its pathogenesis and natural history. Increased revascularisation has been decisive in improving outcomes. However, there is still a need for further improvement. Advances in the treatment of ischaemia in the diabetic foot include therapeutic angiogenesis, stem cell therapy and miscellaneous modalities. Angiogenesis has yielded encouraging results in the treatment of peripheral arterial disease, but it has not been studied enough in patients with diabetes. Choice of patients, reliable study endpoints, as well as safety of growth factors in diabetic patients, who have an excess risk of widespread vascular disease, need to be addressed more convincingly. Similar improvement is required in the other emerging therapeutic options. From a practical point of view, until novel modalities are available, increased vigilance and prompt aggressive revascularisation are indispensable to reduce the rate of amputations.
Export Options
About this article
Cite this article as:
Papanas Nikolaos and Maltezos Efstratios, Advances in Treating the Ischaemic Diabetic Foot, Current Vascular Pharmacology 2008; 6 (1) . https://dx.doi.org/10.2174/157016108783331330
DOI https://dx.doi.org/10.2174/157016108783331330 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
C-Reactive Protein and Hypertension: Is there A Causal Relationship?
Current Pharmaceutical Design The Role of Platelets in Bone Remodeling
Inflammation & Allergy - Drug Targets (Discontinued) Implications of microRNAs in the Pathogenesis of Atherosclerosis and Prospects for Therapy
Current Drug Targets Gene Therapy Approaches for the Prevention of Restenosis
Current Vascular Pharmacology Posture and Gait Biomechanical Aspects during Pregnancy and the Importance of Therapeutic Exercise: Literature Review
Current Women`s Health Reviews The Contribution of Buckwheat Genetic Resources to Health and Dietary Diversity
Current Genomics Relationship between Hyperlipidemia, Cardiovascular Disease and Stroke: A Systematic Review
Current Cardiology Reviews Hyper-Coagulable Profile with Elevated Pro-Thrombotic Biomarkers and Increased Cerebro- and Cardio-Vascular Disease Risk Exist Among Healthy Dyslipidemic Women
Current Neurovascular Research DNA-Damaging Anticancer Drugs – A Perspective for DNA Repair- Oriented Therapy
Current Medicinal Chemistry The Role of Diabetes Mellitus in Sexual and Reproductive Health: An Overview of Pathogenesis, Evaluation, and Management
Current Diabetes Reviews Oleocanthal, a Natural anti-Inflammatory Compound in Extra Virgin Olive Oil
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Vascular Endothelin System in Hypertension - Recent Patents and Discoveries
Recent Patents on Cardiovascular Drug Discovery Human Tissue Kallikrein: A New Bullet for the Treatment of Ischemia
Current Pharmaceutical Design PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Induction of Myocardial Fibrosis and Hypertrophy by Natriuretic Peptides
Vascular Disease Prevention (Discontinued) Biodegradable and Bioabsorbable Stents
Current Pharmaceutical Design Novel Coronavirus SARS-CoV-2 (COVID-19) and Pregnancy: A Hypothetical View
Endocrine, Metabolic & Immune Disorders - Drug Targets Cardiovascular Alterations After Spinal Cord Injury: An Overview
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Adenosine Receptors: New Therapeutic Targets for Inflammation in Diabetic Nephropathy
Inflammation & Allergy - Drug Targets (Discontinued) The Production of Solid Dosage Forms from Non-Degradable Polymers
Current Pharmaceutical Design